Quality-of-life impairment in depressive and anxiety disorders

被引:683
作者
Rapaport, MH
Clary, C
Fayyad, R
Endicott, J
机构
[1] Cedars Sinai Med Ctr, Dept Psychiat, Thalians Mental Hlth Ctr C301, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Coll Phys & Surg, New York, NY USA
关键词
D O I
10.1176/appi.ajp.162.6.1171
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Previous reports demonstrating quality-of-life impairment in anxiety and affective disorders have relied upon epidemiological samples or relatively small clinical studies. Administration of the same quality-of-life scale, the Quality of Life Enjoyment and Satisfaction Questionnaire, to subjects entering multiple large-scale trials for depression and anxiety disorders allowed us to compare the impact of these disorders on quality of life. Method: Baseline Quality of Life Enjoyment and Satisfaction Questionnaire, demographic, and clinical data from 11 treatment trials, including studies of major depressive disorder, chronic/double depression, dysthymic disorder, panic disorder, obsessive-compulsive disorder (OCD), social phobia, premenstrual dysphoric disorder, and posttraumatic stress disorder (PTSD) were analyzed. Results: The proportion of patients with clinically severe impairment ( two or more standard deviations below the community norm) in quality of life varied with different diagnoses: major depressive disorder (63%), chronic/double depression (85%), dysthymic disorder (56%), panic disorder (20%), OCD (26%), social phobia (21%), premenstrual dysphoric disorder (31%), and PTSD (59%). Regression analyses conducted for each disorder suggested that illness-specific symptom scales were significantly associated with baseline quality of life but explained only a small to modest proportion of the variance in Quality of Life Enjoyment and Satisfaction Questionnaire scores. Conclusions: Subjects with affective or anxiety disorders who enter clinical trials have significant quality-of-life impairment, although the degree of dysfunction varies. Diagnostic-specific symptom measures explained only a small proportion of the variance in quality of life, suggesting that an individual's perception of quality of life is an additional factor that should be part of a complete assessment.
引用
收藏
页码:1171 / 1178
页数:8
相关论文
共 55 条
[1]   Posttraumatic stress disorder, tenderness and fibromyalgia [J].
Amir, M ;
Kaplan, Z ;
Neumann, L ;
Sharabani, R ;
Shani, N ;
Buskila, D .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 1997, 42 (06) :607-613
[2]  
[Anonymous], J ANXIETY DISORD
[3]   Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia [J].
Antony, MM ;
Roth, D ;
Swinson, RP ;
Huta, V ;
Devins, GM .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1998, 186 (05) :311-315
[4]   Quality of life in anxiety and social phobia [J].
Bech, P ;
Angst, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 :97-100
[5]   Functional impairment and co-occurring psychiatric disorders in medically hospitalized men [J].
Booth, BM ;
Blow, FC ;
Cook, CAL .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (14) :1551-1559
[6]   Efficacy and safety of sertraline treatment of posttraumatic stress disorder - A randomized controlled trial [J].
Brady, K ;
Pearlstein, T ;
Asnis, GM ;
Baker, D ;
Rothbaum, B ;
Sikes, CR ;
Farfel, GM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (14) :1837-1844
[7]   DEPRESSION, DISABILITY DAYS, AND DAYS LOST FROM WORK IN A PROSPECTIVE EPIDEMIOLOGIC SURVEY [J].
BROADHEAD, WE ;
BLAZER, DG ;
GEORGE, LK ;
CHIU, KT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (19) :2524-2528
[8]   Quality of life in patients with panic disorder [J].
Candilis, PJ ;
McLean, RYS ;
Otto, MW ;
Manfro, GG ;
Worthington, JJ ;
Penava, SJ ;
Marzol, PC ;
Pollack, MH .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1999, 187 (07) :429-434
[9]  
DOLAN RT, 1999, 1999 I PSYCH SERV AM
[10]  
ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321